BCAX (Bicara Therapeutics) Long-Term Capital Lease Obligation : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Long-Term Capital Lease Obligation?

Bicara Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil.

Bicara Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 ($0.14 Mil) to Dec. 2024 ($0.13 Mil) and declined from Dec. 2024 ($0.13 Mil) to Mar. 2025 ($0.00 Mil).

Bicara Therapeutics's annual Long-Term Capital Lease Obligation increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.37 Mil) but then declined from Dec. 2023 ($0.37 Mil) to Dec. 2024 ($0.13 Mil).

Bicara Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Bicara Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Long-Term Capital Lease Obligation Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

0.37

0.13

Bicara Therapeutics Quarterly Data
	Dec22	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial			-	0.22	0.14	0.13	-

Bicara Therapeutics (NAS:BCAX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Bicara Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

https://www.bicara.com

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.